Jorge Barriuso
@drjorgebarriuso.bsky.social
Consultant (clinician-scientist) in medical oncology with an interest in Lower GI malignancies including appendix tumours and peritoneal metastasis. #H12O #imas12 #rarecancers #translationalresearch #drugdevelopment
Reposted by Jorge Barriuso
People with a history of polyps often do not get follow-up colonoscopy after a positive FIT test, early-onset cancers are rising in Corn Belt states, and more. Read these stories and more from Cancer Today magazine's Week in Cancer News. www.cancertodaymag.org/cancer-talk/...
October 31, 2025 at 7:59 PM
People with a history of polyps often do not get follow-up colonoscopy after a positive FIT test, early-onset cancers are rising in Corn Belt states, and more. Read these stories and more from Cancer Today magazine's Week in Cancer News. www.cancertodaymag.org/cancer-talk/...
Reposted by Jorge Barriuso
#ESMO25: First evidence for the efficacy and safety of #TargetedTherapy in #mesothelioma reported as two novel TEAD inhibitors show clinical activity and manageable toxicity in heavily pre-treated patients.
📌Read more in the #ESMODailyReporter https://ow.ly/FARM50XkmWE
📌Read more in the #ESMODailyReporter https://ow.ly/FARM50XkmWE
October 30, 2025 at 5:01 PM
#ESMO25: First evidence for the efficacy and safety of #TargetedTherapy in #mesothelioma reported as two novel TEAD inhibitors show clinical activity and manageable toxicity in heavily pre-treated patients.
📌Read more in the #ESMODailyReporter https://ow.ly/FARM50XkmWE
📌Read more in the #ESMODailyReporter https://ow.ly/FARM50XkmWE
This is a really interesting piece of work if you are interested in spatial transcriptomics (ST).
👉 for single cell studies image based ST seems more appropriate
👉for spatial analysis of bigger regions sequencing based ST might be a better choice
www.nature.com/articles/s41...
👉 for single cell studies image based ST seems more appropriate
👉for spatial analysis of bigger regions sequencing based ST might be a better choice
www.nature.com/articles/s41...
Systematic benchmarking of high-throughput subcellular spatial transcriptomics platforms across human tumors - Nature Communications
This study benchmarks four cutting-edge spatial transcriptomics platforms using human tumour tissues, performs multi-metric evaluation with multi-omics references, and presents the SPATCH portal for v...
www.nature.com
October 25, 2025 at 9:46 AM
This is a really interesting piece of work if you are interested in spatial transcriptomics (ST).
👉 for single cell studies image based ST seems more appropriate
👉for spatial analysis of bigger regions sequencing based ST might be a better choice
www.nature.com/articles/s41...
👉 for single cell studies image based ST seems more appropriate
👉for spatial analysis of bigger regions sequencing based ST might be a better choice
www.nature.com/articles/s41...
Reposted by Jorge Barriuso
#ESMO25: Novel tissue-agnostic biomarker approaches utilising the latest technology, including cutting-edge #AI-driven #DigitalPathology, could improve #immunotherapy response through optimised patient selection.
More in the #ESMODailyReporter ➡️ https://ow.ly/smhA50XeYLq
More in the #ESMODailyReporter ➡️ https://ow.ly/smhA50XeYLq
October 20, 2025 at 5:30 PM
#ESMO25: Novel tissue-agnostic biomarker approaches utilising the latest technology, including cutting-edge #AI-driven #DigitalPathology, could improve #immunotherapy response through optimised patient selection.
More in the #ESMODailyReporter ➡️ https://ow.ly/smhA50XeYLq
More in the #ESMODailyReporter ➡️ https://ow.ly/smhA50XeYLq
Another outstanding discussion from Dra. Elena Élez on WSI H&Es AI used to predict response on the italian ATEZOTRIBE / AVATRIC cohorts and STELLAR-303.
👉 What about microbiome and tertiary lymphoid structures (TLS)
👉More translational studies needed
#ESMO25 @myesmo.bsky.social
👉 What about microbiome and tertiary lymphoid structures (TLS)
👉More translational studies needed
#ESMO25 @myesmo.bsky.social
October 20, 2025 at 8:14 AM
Another outstanding discussion from Dra. Elena Élez on WSI H&Es AI used to predict response on the italian ATEZOTRIBE / AVATRIC cohorts and STELLAR-303.
👉 What about microbiome and tertiary lymphoid structures (TLS)
👉More translational studies needed
#ESMO25 @myesmo.bsky.social
👉 What about microbiome and tertiary lymphoid structures (TLS)
👉More translational studies needed
#ESMO25 @myesmo.bsky.social
An amazing discussion by Dr Sharlene Gill on the updates of CHECKMATE 8HW and BREAKWATER.
👉 Can we identify patients deriving benefit from single agent IO in MMRd /MSI-H metastatic CRC?
👉Is there any room to rechallenge in BRAF mCRC?
#ESMODailyReporter @myesmo.bsky.social
👉 Can we identify patients deriving benefit from single agent IO in MMRd /MSI-H metastatic CRC?
👉Is there any room to rechallenge in BRAF mCRC?
#ESMODailyReporter @myesmo.bsky.social
October 20, 2025 at 7:58 AM
An amazing discussion by Dr Sharlene Gill on the updates of CHECKMATE 8HW and BREAKWATER.
👉 Can we identify patients deriving benefit from single agent IO in MMRd /MSI-H metastatic CRC?
👉Is there any room to rechallenge in BRAF mCRC?
#ESMODailyReporter @myesmo.bsky.social
👉 Can we identify patients deriving benefit from single agent IO in MMRd /MSI-H metastatic CRC?
👉Is there any room to rechallenge in BRAF mCRC?
#ESMODailyReporter @myesmo.bsky.social
Reposted by Jorge Barriuso
🎥 50 years of key moments.
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
October 19, 2025 at 1:49 PM
🎥 50 years of key moments.
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
ESMO’s 50th anniversary marks decades of achievements in #ScienceDissemination, #education and #collaboration. Take a selfie and share one of your milestones with #myESMOStory. #ESMO25
🔗 www.youtube.com/watch?v=dJTH...
Reposted by Jorge Barriuso
#ESMO25: Clinically relevant survival benefits reported in platinum-resistant #OvarianCancer with pembrolizumab plus weekly paclitaxel with or without bevacizumab in ENGOT-ov65/KEYNOTE-B96 #ESMODailyReporter 👉https://ow.ly/MIjA50XeuR3
#immunotherapy
#immunotherapy
October 18, 2025 at 4:01 PM
#ESMO25: Clinically relevant survival benefits reported in platinum-resistant #OvarianCancer with pembrolizumab plus weekly paclitaxel with or without bevacizumab in ENGOT-ov65/KEYNOTE-B96 #ESMODailyReporter 👉https://ow.ly/MIjA50XeuR3
#immunotherapy
#immunotherapy
Deeply honoured for participating in #ESSO44 Gothenburg as speaker in the session Progress in Pseudomyxoma Peritonei Therapy! @essonews.bsky.social
To Berlin now for an exciting #ESMO25 @myesmo.bsky.social #ESMODailyReporter
and shortly see you at PSOGI meeting in Barcelona
To Berlin now for an exciting #ESMO25 @myesmo.bsky.social #ESMODailyReporter
and shortly see you at PSOGI meeting in Barcelona
October 16, 2025 at 1:43 PM
Deeply honoured for participating in #ESSO44 Gothenburg as speaker in the session Progress in Pseudomyxoma Peritonei Therapy! @essonews.bsky.social
To Berlin now for an exciting #ESMO25 @myesmo.bsky.social #ESMODailyReporter
and shortly see you at PSOGI meeting in Barcelona
To Berlin now for an exciting #ESMO25 @myesmo.bsky.social #ESMODailyReporter
and shortly see you at PSOGI meeting in Barcelona
Much needed collaboration between @myesmo.bsky.social and ESTRO !
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors - Annals of Oncology www.annalsofoncology.org/article/S092...
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors - Annals of Oncology www.annalsofoncology.org/article/S092...
October 4, 2025 at 4:14 PM
Much needed collaboration between @myesmo.bsky.social and ESTRO !
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors - Annals of Oncology www.annalsofoncology.org/article/S092...
ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors - Annals of Oncology www.annalsofoncology.org/article/S092...
Reposted by Jorge Barriuso
How does #ESMOMCBS v2.0 reflect the evolving #oncology treatment landscape and the priorities of #PatientsWithCancer? Sjoukje Oosting shares her insights in the #ESMODailyReporter.
🔗 ow.ly/8aJt50WBROf
🔗 ow.ly/8aJt50WBROf
August 8, 2025 at 7:55 AM
How does #ESMOMCBS v2.0 reflect the evolving #oncology treatment landscape and the priorities of #PatientsWithCancer? Sjoukje Oosting shares her insights in the #ESMODailyReporter.
🔗 ow.ly/8aJt50WBROf
🔗 ow.ly/8aJt50WBROf
Reposted by Jorge Barriuso
#ESMOTATAsia25: Presentations highlight the value of integrating #PatientReportedOutcomes (#PRO) into #EarlyPhaseTrials with guidance on standardisation.
Read more in the #ESMODailyReporter
🔗 dailyreporter.esmo.org/esmo-targete...
Read more in the #ESMODailyReporter
🔗 dailyreporter.esmo.org/esmo-targete...
July 18, 2025 at 7:58 AM
#ESMOTATAsia25: Presentations highlight the value of integrating #PatientReportedOutcomes (#PRO) into #EarlyPhaseTrials with guidance on standardisation.
Read more in the #ESMODailyReporter
🔗 dailyreporter.esmo.org/esmo-targete...
Read more in the #ESMODailyReporter
🔗 dailyreporter.esmo.org/esmo-targete...
Reposted by Jorge Barriuso
#ESMOTATAsia25: In an Opinion piece in the #ESMODailyReporter, Lillian Siu discusses the growth of early #oncology #ClinicalTrials in #AsiaPacific but highlights the need for improved trial access in low- and middle-income countries.
🔗 dailyreporter.esmo.org/esmo-targete...
🔗 dailyreporter.esmo.org/esmo-targete...
July 19, 2025 at 6:55 AM
#ESMOTATAsia25: In an Opinion piece in the #ESMODailyReporter, Lillian Siu discusses the growth of early #oncology #ClinicalTrials in #AsiaPacific but highlights the need for improved trial access in low- and middle-income countries.
🔗 dailyreporter.esmo.org/esmo-targete...
🔗 dailyreporter.esmo.org/esmo-targete...
Reposted by Jorge Barriuso
#ESMOTATAsia25: Exploratory #omics and #MachineLearning revealed an 11-gene signature associated with response after #chemoradiotherapy for #CervicalCancer. MMP2 was identified as a key target.
Read more in the #ESMODailyReporter
🔗 buff.ly/cHluzz7
Read more in the #ESMODailyReporter
🔗 buff.ly/cHluzz7
July 19, 2025 at 8:15 AM
#ESMOTATAsia25: Exploratory #omics and #MachineLearning revealed an 11-gene signature associated with response after #chemoradiotherapy for #CervicalCancer. MMP2 was identified as a key target.
Read more in the #ESMODailyReporter
🔗 buff.ly/cHluzz7
Read more in the #ESMODailyReporter
🔗 buff.ly/cHluzz7
Such a pleasure to work with this team!!
#ESMO25 is just a few months ahead!
#ESMO25 is just a few months ahead!
The ESMO Communication Committee (in-person in Lugano + online) all hyped up - as we spent the past few weeks + all day today discussing & planning for #ESMO25 Congress.
Watch the space for Berlin 2025 🙌!
@myesmo.bsky.social
#BreakingNews
#PracticeChanging #ONEOncologyCommunity #educationforLIFE
Watch the space for Berlin 2025 🙌!
@myesmo.bsky.social
#BreakingNews
#PracticeChanging #ONEOncologyCommunity #educationforLIFE
July 15, 2025 at 8:03 PM
Such a pleasure to work with this team!!
#ESMO25 is just a few months ahead!
#ESMO25 is just a few months ahead!
Thank you @myesmo.bsky.social #ESMOGI2025 chairs & organizing committee to bring GI #rarecancers to the stage and having me in good company. I hope I brought some awareness to #appendixcancers #pseudomyxoma #peritonealmesothelioma
#ESMOAmbassadors
@acpmpresearch.bsky.social
#ESMOAmbassadors
@acpmpresearch.bsky.social
July 6, 2025 at 9:16 AM
Thank you @myesmo.bsky.social #ESMOGI2025 chairs & organizing committee to bring GI #rarecancers to the stage and having me in good company. I hope I brought some awareness to #appendixcancers #pseudomyxoma #peritonealmesothelioma
#ESMOAmbassadors
@acpmpresearch.bsky.social
#ESMOAmbassadors
@acpmpresearch.bsky.social
Interesting mini-Oral presentation from Dr Francesca Negri about the assessment of tumour immune microenvironment as a prognostic marker in Locally Advanced Rectal Cancer using a cohort from STAR-01 #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors
July 5, 2025 at 7:51 AM
Interesting mini-Oral presentation from Dr Francesca Negri about the assessment of tumour immune microenvironment as a prognostic marker in Locally Advanced Rectal Cancer using a cohort from STAR-01 #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors
Impressive review of the use of blood based assays for screening in Colorectal Cancer at #ESMOGI25 by Prof Sinicrope
Take a closer look at the takeaway points!! @myesmo.bsky.social #ESMOAmbassadors
Take a closer look at the takeaway points!! @myesmo.bsky.social #ESMOAmbassadors
July 4, 2025 at 8:40 AM
Impressive review of the use of blood based assays for screening in Colorectal Cancer at #ESMOGI25 by Prof Sinicrope
Take a closer look at the takeaway points!! @myesmo.bsky.social #ESMOAmbassadors
Take a closer look at the takeaway points!! @myesmo.bsky.social #ESMOAmbassadors
AI revolution coming to #ESMOGI25 Very interesting presentations from Prof Magali Svrcek and @jnkt.bsky.social about the use and potential of #ArtificialIntelligence @myesmo.bsky.social #ESMOAmbassadors
July 3, 2025 at 10:09 AM
AI revolution coming to #ESMOGI25 Very interesting presentations from Prof Magali Svrcek and @jnkt.bsky.social about the use and potential of #ArtificialIntelligence @myesmo.bsky.social #ESMOAmbassadors
Amazing trip through translational research in colorectal cancer from Sanger sequencing to Single Cell by Prof. Federica de Nicolantonio at @myesmo.bsky.social #ESMOGI25 #ESMOAmbassadors
July 3, 2025 at 8:43 AM
Amazing trip through translational research in colorectal cancer from Sanger sequencing to Single Cell by Prof. Federica de Nicolantonio at @myesmo.bsky.social #ESMOGI25 #ESMOAmbassadors
Starting the 2nd day at @myesmo.bsky.social #ESMOGI25 with a Multidisciplinary Tumour Board in Rectal Cancer! #ESMOAmbassadors
July 3, 2025 at 7:11 AM
Starting the 2nd day at @myesmo.bsky.social #ESMOGI25 with a Multidisciplinary Tumour Board in Rectal Cancer! #ESMOAmbassadors
This is really very clever science!!! www.cell.com/cancer-cell/...
A first-in-class EGFR-directed KRAS G12V selective inhibitor
Despite KRAS G12V being a common mutation in cancer, no direct inhibitors currently
exist. Stanland et al. demonstrate that an EGFR-directed RNAi platform, EFTX-G12V,
selectively targets KRAS G12V whi...
www.cell.com
June 21, 2025 at 1:27 PM
This is really very clever science!!! www.cell.com/cancer-cell/...
Reposted by Jorge Barriuso
ESMO-MCBS v2.0 is now out. Significant enhancements in cancer therapies evaluation:
> robust
🔍 understanding of score’s meaning,
➕ accuracy, fairness, utility of treatment assessments,
🪞 advances in science, clinical practice, patient input.
> robust
🔍 understanding of score’s meaning,
➕ accuracy, fairness, utility of treatment assessments,
🪞 advances in science, clinical practice, patient input.
May 23, 2025 at 6:49 AM
ESMO-MCBS v2.0 is now out. Significant enhancements in cancer therapies evaluation:
> robust
🔍 understanding of score’s meaning,
➕ accuracy, fairness, utility of treatment assessments,
🪞 advances in science, clinical practice, patient input.
> robust
🔍 understanding of score’s meaning,
➕ accuracy, fairness, utility of treatment assessments,
🪞 advances in science, clinical practice, patient input.
Reposted by Jorge Barriuso
As the #oncology field evolves, ESMO is keeping pace - regularly ensuring its tools reflect the latest in #ClinicalEvidence and regulatory shifts. An important evolution is just around the corner — keep an eye out.
#ESMOMCBS
#ESMOMCBS
May 16, 2025 at 12:49 PM
As the #oncology field evolves, ESMO is keeping pace - regularly ensuring its tools reflect the latest in #ClinicalEvidence and regulatory shifts. An important evolution is just around the corner — keep an eye out.
#ESMOMCBS
#ESMOMCBS
The Manchester Colorectal and Peritoneal Oncology Centre (CPOC) experience in colorectal peritoneal metastasis management is out in press!
More clinical trials are needed in this space after PRODIGE-7!
www.clinical-colorectal-cancer.com/article/S153...
More clinical trials are needed in this space after PRODIGE-7!
www.clinical-colorectal-cancer.com/article/S153...
Oncological outcomes from cytoreductive surgery and heated intraperitoneal chemotherapy for colorectal cancer peritoneal metastases
The peritoneum is the third most common site of recurrence in colorectal cancer (CRC)1,2. Colorectal cancer peritoneal metastases (CRPM) are associated with poorer overall survival (OS) compared to other metastatic sites3 and systemic anticancer treatment (SACT) alone offers 3-16 months median OS benefit4–7. Cytoreductive surgery (CRS) was shown to achieve OS of over 40 months in the phase III randomised controlled trial (RCT) (PRODIGE-7)8. The addition of Oxaliplatin heated intraperitoneal chemotherapy (HIPEC) did not significantly prolong OS (CRS alone=41.2 months, CRS+HIPEC=41.7 months; p=0.99).Consequently, international guidelines have recommended CRS for resectable CRPM, but advised against using HIPEC outside clinical trials8–10.
www.clinical-colorectal-cancer.com
December 19, 2024 at 5:21 PM
The Manchester Colorectal and Peritoneal Oncology Centre (CPOC) experience in colorectal peritoneal metastasis management is out in press!
More clinical trials are needed in this space after PRODIGE-7!
www.clinical-colorectal-cancer.com/article/S153...
More clinical trials are needed in this space after PRODIGE-7!
www.clinical-colorectal-cancer.com/article/S153...